through the Custom Array laboratory. This second laboratory also supports the import and development of new array technologies e.g., micro-RNA arrays, that are of particular relevance to the current proposal. The Custom Array laboratory has been in operation for 7 years, and has processed over 5,500 samples to date. Core B is investing continually in state-of-the-art instrumentation: recent enhancements include a new spotted array printer (Qarray2) and several new Affymetrix fluidics workstations and scanners (in total 8 fluidics workstations and 3 high-resolution scanners each with autosamplers). Together, these laboratories have produced and assisted in the analysis of over 27,000 microarray profiles, thereby contributing critically to the research of this Program and other laboratories across SJCRH. Core B also includes substantial bioinformatics and biostatistics expertise that will provide support and computational hardware to the Program. These resources that are crucial for the completion of array based experiments include eight Ph.D.-level bioinformaticists (one of which is dedicated to this P01, Dr. Chunxu Qu) and 12 other highly skilled technical staff. Drs. Pounds and Zhao, who are faculty members in Biostatistics, also bring unique and extensive expertise in microarray data analysis. The high performance computing facility associated with Core B includes a 420-cpu Linux cluster, 150 Tb storage capacity, and a wealth of bioinformatics applications including LaserGene, Affymetrix LIMS system, Spotfire DecisionSite, R, and many other applications suitable for sequence and gene expression analysis. We seek partial support for one bioinformaticist dedicated to this Program (Dr. Chunxu Qu).

Public Health Relevance

To provide molecular profiling and bioinformatics support for investigation of pediatric brain tumors PROJECT/

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA096832-10
Application #
8459555
Study Section
Special Emphasis Panel (ZCA1-GRB-S)
Project Start
Project End
Budget Start
2013-04-01
Budget End
2014-03-31
Support Year
10
Fiscal Year
2013
Total Cost
$155,078
Indirect Cost
$52,172
Name
St. Jude Children's Research Hospital
Department
Type
DUNS #
067717892
City
Memphis
State
TN
Country
United States
Zip Code
38105
Pajtler, Kristian W; Wen, Ji; Sill, Martin et al. (2018) Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas. Acta Neuropathol 136:211-226
Teitz, Tal; Fang, Jie; Goktug, Asli N et al. (2018) CDK2 inhibitors as candidate therapeutics for cisplatin- and noise-induced hearing loss. J Exp Med 215:1187-1203
Tsang, Derek S; Burghen, Elizabeth; Klimo Jr., Paul et al. (2018) Outcomes After Reirradiation for Recurrent Pediatric Intracranial Ependymoma. Int J Radiat Oncol Biol Phys 100:507-515
Shadrick, William R; Slavish, Peter J; Chai, Sergio C et al. (2018) Exploiting a water network to achieve enthalpy-driven, bromodomain-selective BET inhibitors. Bioorg Med Chem 26:25-36
Roussel, Martine F; Stripay, Jennifer L (2018) Epigenetic Drivers in Pediatric Medulloblastoma. Cerebellum 17:28-36
Waszak, Sebastian M; Northcott, Paul A; Buchhalter, Ivo et al. (2018) Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. Lancet Oncol 19:785-798
El Nagar, Salsabiel; Zindy, Frederique; Moens, Charlotte et al. (2018) A new genetically engineered mouse model of choroid plexus carcinoma. Biochem Biophys Res Commun 496:568-574
Nimmervoll, Birgit V; Boulos, Nidal; Bianski, Brandon et al. (2018) Establishing a Preclinical Multidisciplinary Board for Brain Tumors. Clin Cancer Res 24:1654-1666
Vo, BaoHan T; Kwon, Jin Ah; Li, Chunliang et al. (2018) Mouse medulloblastoma driven by CRISPR activation of cellular Myc. Sci Rep 8:8733
Wei, Lei; Murphy, Brian L; Wu, Gang et al. (2017) Exome sequencing analysis of murine medulloblastoma models identifies WDR11 as a potential tumor suppressor in Group 3 tumors. Oncotarget 8:64685-64697

Showing the most recent 10 out of 208 publications